NIH launches program to map a rare type of non-dividing cells implicated in human health and disease

Oct. 21, 2021

The National Institutes of Health has launched a program to study a rare type of cells, called “senescent” cells, that play both positive and negative roles in biological processes. The NIH Common Fund’s Cellular Senescence Network (SenNet) program will leverage recent advances in studying individual cells, or single-cell analysis, to comprehensively identify and characterize the differences in senescent cells across the body, across various states of human health, and across the lifespan.

The rarity and diversity of these cells previously made them difficult to identify and study; therefore, a deeper understanding will help researchers develop therapies that encourage beneficial effects of senescent cells while suppressing their tissue-damaging effects.

“The number of senescent cells in a person’s body increases with age, which may reflect both an increase in the generation of these cells and a decreased ability of the aging immune system to regulate or eliminate these cells. This age-related accumulation of senescent cells leads to production of inflammatory molecules and corruption of healthy cells,” said Richard J. Hodes, M.D., director of the National Institute on Aging, part of NIH. “This can affect a person’s ability to withstand stress or illness, recuperate from injuries, and maintain normal brain function. The aim of NIH’s strengthened focus on this field of science is to one day conquer these and other challenges.”

A cell dividing into two cells is a hallmark of human development. Over time, our bodies accumulate a small number of cells that no longer divide. These “senescent” cells can play important roles in health, either directly or through the release of molecules that affect neighboring cells. Senescent cells can play positive roles, such as aiding wound repair or preventing tumor growth in some cancers. However, they can also contribute to chronic diseases of aging such as cardiovascular disease and neurodegeneration. For this reason, therapeutics called “senolytics” are being developed to target senescent cells and remove them from the body.

“The study of senescent cells holds great promise in helping to assess the role of these cells in the development of age-related disease, including cancer,” said Norman E. “Ned” Sharpless, M.D., director of NIH’s National Cancer Institute. “Cancer is certainly one of the most prevalent chronic age-related diseases. We look forward to the potential translational benefits of this research in answering some of the most challenging questions about aging and cancer. This initiative will advance our work in the cancer research field overall.”

NIH is funding $125 million to 16 grants over five years, pending available funds. NIH issued eight awards for the creation of SenNet Tissue Mapping Centers, seven awards for Technology Development and Application Projects, and one award for a Consortium Organization and Data Coordinating Center (CODCC). The Tissue Mapping Centers will identify biomarkers of senescent cells in humans and then construct high-resolution, detailed maps of cellular senescence across the lifespan and physiological states.

The Technology Development and Application Projects will be critical in advancing promising tools, techniques, and methods for SenNet to study senescent cells. As the organizational hub, the CODCC will collect, store, and curate the Network’s data, tools, and models. These projects will work together to create a publicly accessible and searchable Atlas of Cellular Senescence. The SenNet program accelerates the ability of biomedical researchers to develop therapeutics that target cellular senescence and improve human health by providing data and resources that would be difficult to achieve through individual efforts.

The SenNet program is a trans-NIH effort managed collaboratively by staff from the NIH Common Fund, the National Institute on Aging, and the National Cancer Institute.

NIH report